Overview

Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid Tumor

Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
Thirty patients with desmoid tumors (invasive fibromatosis) will be recruited in the Department of Bone and Soft Tissue, Henan Cancer Hospital. This is a prospective, multicenter, single-arm clinical study to evaluate the efficacy and safety of anlotinib combined with chemotherapy in the treatment of inoperable advanced desmoid tumors.
Phase:
N/A
Details
Lead Sponsor:
Henan Cancer Hospital